I**JB**MS

Investigating the protective effects of fluvoxamine against sepsis-related acute lung injury through antiapoptotic, antiinflammatory, and anti-oxidant features in rats

Halil Asci^{1, 2}, Suleyman Emre Akin³, Hasan Ekrem Camas³, Ahmet Bindal⁴, Okan Kurtbolat¹, Serife Tasan⁵, Abdurrahman Gulal⁶, Rumeysa Taner², Turgut Kurt⁷, Ozlem Ozmen^{5*}

¹ Department of Pharmacology, Faculty of Medicine, Suleyman Demirel University, Isparta, Turkey

² Department of Bioengineering, Institute of Science and Technology, Suleyman Demirel University Isparta, Turkey

³ Department of Thoracic Surgery, Faculty of Medicine, Suleyman Demirel University, Isparta, Turkey

⁴ Department of Anesthesiology and Reanimation, Suleyman Demirel University, Isparta, Turkey

⁵ Department of Pathology, Faculty of Veterinary Medicine, Burdur Mehmet Akif Ersoy University, Burdur, Turkey

⁶ Veterinarian, Isparta, Turkey

⁷ Veterinary Technician, Faculty of Medicine, Suleyman Demirel University Isparta, Turkey

ARTICLE INFO

Article type: Original

Article history: Received: Jun 18, 2024 Accepted: Oct 12, 2024

Keywords: ER stress Inflammation Lipopolysaccharide Rat Respiratory system SSRI

ABSTRACT

Objective(s): Acute lung injury (ALI) is characterized by severe hypoxia and alveolar damage, often caused by oxidative stress, endoplasmic reticulum stress (ERS), and apoptosis. Fluvoxamine (FLV), an antidepressant, has tissue-protective properties through various intracellular mechanisms. This study investigates the anti-inflammatory effects of FLV used as an antidepressant in a lipopolysaccharide (LPS)-induced ALI model.

Materials and Methods: Thirty-two female Wistar Albino rats aged 14–16 weeks and weighing 300– 350 g, with 8 animals in each group, were divided into four groups: control, LPS, LPS+FLV, and FLV. After LPS administration, rats were euthanized, and histopathological analysis, immunohistochemistry for tumor necrosis factor-α (TNF-α) and caspase-3 (Cas-3), ELISA for oxidative stress markers, and PCR for CHOP, Cas-12, and Cas-9 gene expressions were conducted.

Results: In the LPS group, lung tissue damage, increased inflammatory cell infiltration, increased Cas-3 and TNF- α expressions, increased oxidative stress markers, and increased CHOP, Cas-9, and Cas-12 mRNA expressions were observed compared to the control group. FLV treatment in the LPS+FLV group significantly reversed these effects in the LPS group.

Conclusion: FLV exhibits protective effects against ALI by mitigating inflammation, ERS, and apoptosis via the CHOP/Cas-9/Cas-12 pathway. Further studies are needed to explore additional pathways and potential clinical applications of FLV.

► Please cite this article as:

Asci H, Akin SE, Camas HE, Bindal A, Kurtbolat O, Tasan S, Gulal A, Taner R, Kurt T, Ozmen O. Investigating the protective effects of fluvoxamine against sepsis-related acute lung injury through antiapoptotic, anti-inflammatory, and anti-oxidant features in rats. Iran J Basic Med Sci 2025; 28: 323-331. doi: https://dx.doi.org/10.22038/ijbms.2024.80608.17444

Introduction

The systemic inflammatory response is a crucial aspect of the body's immune system, designed to combat external pathogens like bacteria, viruses, and fungi while preventing infections. However, an excessive inflammatory response can lead to tissue damage. This response affects various organs and tissues, including the respiratory system, which can result in sepsis-related acute lung injury (ALI)(1).

ALI manifests as severe hypoxia and extensive damage to the alveoli, often progressing to acute respiratory distress syndrome (ARDS) and respiratory failure, often with fatal outcomes. The onset of ALI is typically marked by the infiltration of inflammatory cells, particularly neutrophils and macrophages, into the lungs (2). This infiltration triggers the hyperactivation of these inflammatory cells, leading to the excessive release of pro inflammatory cytokines such as tumor necrosis factor-alpha (TNF- α) (3). Additionally, the heightened inflammatory response results in the accumulation of reactive oxygen species (ROS), which are byproducts of oxidative energy metabolism. ROS accumulation further exacerbates the inflammatory response and tissue damage by inducing cell apoptosis through various signaling pathways (4).

In conditions that provoke an inflammatory response, the endoplasmic reticulum (ER), with its essential role in cell viability, may experience stress known as endoplasmic reticulum stress (ERS). ERS can lead to the accumulation of faulty protein structures and trigger the production of caspase-12 (Cas-12), crucial molecules in ER-induced apoptosis (5). Calpain also plays a significant role in Cas-12 activation. ERS-induced Cas-12 activation initiates apoptosis by activating caspase-3 (Cas-3), the final step in

*Corresponding author: Ozlem Ozmen. Department of Pathology, Faculty of Veterinary Medicine, Burdur Mehmet Akif Ersoy University, Burdur, Turkey. Tel/ Fax: +90-2482132170, Email: ozlemozmen@mehmetakif.edu.tr



© 2025. This work is openly licensed via CC BY 4.0. This is an Open Access article distributed under the terms of the Creative Commons Attribution License (https://creativecommons.org/licenses), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited. the apoptotic pathway mediated by protein kinase R-like ER kinase (PERK)-mediated C/EBP-homologous protein (CHOP). Moreover, ERS can induce apoptosis through mitochondria by upregulating CHOP expression (6, 7). In cases of prolonged ER stress, CHOP is notably upregulated. The activation of mitochondrial stress by CHOP expression decreases antiapoptotic B-cell lymphoma 2 (Bcl-2) levels while increasing apoptotic Bcl-2-associated X-protein (BAX) and Bcl-2 homologous antagonist/killer (BAK) levels. This results in the release of cytochrome C from mitochondria, triggering caspase-9 (Cas-9) activation and ultimately leading to apoptosis associated with Cas-3 activation. Overall, effectively reducing the inflammatory response can halt disease progression (Figure 1)(7, 8).

Fluvoxamine (FLV) is a selective serotonin reuptake inhibitor commonly prescribed for depression and anxiety disorders. Aside from its serotonin-related effects, FLV has a notable affinity for sigma-1 receptors (S1R) found in cells' ER (9). Studies have indicated that FLV can mitigate ERS by reducing CHOP expression (10). Moreover, the protective effects of FLV within these mechanisms have been documented (11, 12).

In this study, our objective was to explore the potential beneficial effects of FLV, which influences the intracellular signaling mechanisms discussed above, on the pathophysiology of ALI.

Materials and Methods

Ethical approval

The procedures carried out on rats were reviewed and approved by the Animal Experiments Local Ethics Committee of Suleyman Demirel University University (Ethics No: 26.01.2023-121/01). The experiment adhered to the ARRIVE 2.0 guidelines. Additionally, support for the study was provided by the Suleyman Demirel University University Scientific Research Project Unit (SDU-BAP) under project number TSG-2023-9010.

Chemicals

LPS was obtained from Sigma Aldrich (L2630-100 mg), USA. FLV, Faverin 100 mg, was obtained from Abbott Ltd. Turkey. For sedation and anesthesia induction, Xylazine Bio 2% (Bioveta, Czech Republic) and Keta-Control (Doga Ilaç, Turkey) were utilized.

For immunohistochemical analysis, the Anti-Cas-3

antibody [EPR18297] (ab184787) and the recombinant anti-TNF- α antibody [RM1005] (ab307164) were used as primary antibodies. The mouse and Rabbit Specific HRP/ AEC (ABC) Detection IHC Kit (ab93705) was used as a secondary antibody, and aminoethyl carbazole (AEC) was used as chromogen. Primary and secondary antibodies were provided by Abcam (Cambridge, UK).

For reverse transcription-polymerase chain reaction (RT-qPCR) analysis, RNA isolation from homogenized tissues was performed using GeneAll RiboEx(TM) RNA Isolation Kit (GeneAll Biotechnology, Seoul, Korea). For cDNA synthesis, 1 μ g RNA was isolated using A.B.T.^{max} cDNA Synthesis Kit (Atlas Biotechnology, Turkey). Gene expression levels were evaluated with a 2X SYBR green master mix kit (Nepenthe, Turkey).

Animals

Thirty-two adult female Wistar albino rats weighing 300-350 g and 14-16 weeks old were housed in standard Eurotype 4 cages, with each group separated from the others. The animals were maintained under controlled environmental conditions, specifically at 55% humidity and 23 °C, following a 12-hour light and 12-hour dark cycle. They were provided *ad libitum* access to standard commercial feed and water. The rats were randomly allocated to groups, and four experimental groups were formed as follows:


Control group (n=8): Intraperitoneal (IP) administration of 0.5–1 ml of normal saline (NS) in the left inguinal region of the rats, followed by IP administration of 0.5 ml of NS in the right inguinal region 30 min later.

LPS group (n=8): IP administration of 0.5-1 ml of NS in the left inguinal region of the rats, followed by IP administration of 0.5 ml of LPS at a dose of 5 mg/kg in the right inguinal region 30 min later. LPS was dissolved in NS (13).

LPS+FLV group (n=8): IP administration of 50 mg/kg FLV in 0.5–1 ml volume of NS in the left inguinal region of the rats, followed by IP administration of 5 mg/kg LPS in 0.5 ml volume in the right inguinal region 30 min later (14).

FLV group (n=8): IP administration of FLV at a dose of 50 mg/kg in 0.5-1 ml volume of NS in the left inguinal region of the rats, followed by IP administration of 0.5 ml NS in the right inguinal region 30 min later.

Six hours after the LPS administration, rats were anesthetized with 90 mg/kg ketamine and 10 mg/kg



LUNG TISSUE

Figure 1. Possible effects of fluvoxamine (FLV) on the lipopolysaccharide (LPS)-induced acute lung injury (ALI) model in rats

xylazine and then sacrificed. Following the abdominal incision, euthanasia was performed by drawing blood from the inferior vena cava. Lung tissues were removed and portioned. The right lung tissues were placed into a 10% formaldehyde solution for histopathological and immunohistochemical evaluations. The left lung tissues were divided into two equal parts, with one part stored at -80 °C for genetic analysis and the other part stored at -20 °C for biochemical analysis.

Biochemical analysis

To initiate the experiment, lung tissues were diluted in phosphate-buffered saline (PBS)(10 mM sodium phosphate) with a five-fold weight/volume ratio, adjusting the pH to 7.4. Subsequently, the tissues underwent homogenization using a tissue homogenizer (IKA Ultra Turrax T25, Janke & Kunkel, Staufen, Germany). Following homogenization, samples were centrifuged at 2000 rpm for 20 min at +4 °C using a Nuve NF 1200R centrifuge (Ankara, Turkey). The supernatant obtained after centrifugation was utilized to measure the concentrations of tissue total anti-oxidant status (TAS) and total oxidant status (TOS). An automated biochemistry analyzer (Beckman Coulter AU 5800, Brea, CA, USA) and colorimetric methods developed by Erel were employed for these assays (15, 16). TOS results were expressed as µmol H2O2 Equiv/g, while TAS results were reported as mmol Trolox Equiv/g. The oxidative stress index (OSI) was calculated by dividing TOS levels by TAS levels, denoted as TOS/TAS/10 (17).

Histopathological analysis

During the necropsy, lung tissue samples were collected and fixed in a 10% buffered formalin solution. After a twoday fixation period, all tissues were routinely processed by an automated tissue processing device and then embedded in paraffin wax. From the paraffin blocks, sections of fivemicron thickness were precisely cut using an automated rotary microtome. These sections were then subjected to hematoxylin-eosin (HE) staining and evaluated under a light microscope for detailed histological analysis (18).

The severity of vascular and alveolar changes, edema, and bronchiole pathology were graded on a scale from 0 (normal) to 3 (severe). The examined features included pulmonary congestion, inflammation, thickening of the alveolar septal tissue, and detachment of the bronchiole epithelium, following modifications by Passmore *et al.* (19). Histopathological scoring criteria are provided in Table 1.

Immunohistochemical analysis

 Table 1. Scoring criterion for pulmonary histopathological lesions

Moreover, following the manufacturer's guidelines, two sets of sections were extracted from each paraffin block and mounted on poly-L-lysine-coated slides for immunohistochemical staining targeting TNF-a and Cas-3 expression. Specifically, these sections were stained using -Cas-3 antibody and TNF-a antibody, with each primary antibody diluted to 1/100. After overnight exposure to the primary antibodies, immunohistochemistry was performed using a streptavidin-alkaline phosphatase conjugate and a biotinylated secondary antibody. The Mouse and Rabbit Specific HRP/AEC (ABC) Detection IHC Kit (ab93705) served as the secondary antibody, and aminoethyl carbazole (AEC) was employed as the chromogen. Both primary and secondary antibodies were supplied by Abcam (Cambridge, UK). Negative controls utilized antigen dilution solution in place of primary antibodies. Evaluation of the samples was conducted by a trained pathologist from another university in a blinded manner.

The percentage of immune-positive cells for each marker in 10 distinct fields on each slide for all groups was calculated at an objective magnification of X40. Image analysis was performed using the ImageJ program (National Institutes of Health, Bethesda, MD, version 1.48). Images were processed by separating them into color channels, cropping, and eliminating any artifacts. Cells within the regions of interest were initially selected using a selection tool, and then the software's counting tool was employed. Strong red staining was used to identify positively stained cells. Microphotographs were captured using the Database Manual Cell Sens Life Science Imaging Software System (Olympus Co., Tokyo, Japan)(20, 21)

Reverse transcription-polymerase chain reaction (RTqPCR)

RNA isolation from homogenized tissues was performed using the GeneAll RiboEx (TM) RNA Isolation Kit (GeneAll Biotechnology, Seoul, Korea) following the manufacturer's protocol. The quantity and purity of the obtained RNAs were assessed using the BioSpec-nano nanodrop device (Shimadzu Ltd., Kyoto, Japan). For cDNA synthesis, 1 µg of RNA was utilized with the A.B.T. [™] cDNA Synthesis Kit (Atlas Biotechnology, Turkey) in a thermal cycler as per the provided protocol. Primer sequences were designed based on specific mRNA sequences, and potential primer sequences were evaluated using the NCBI website. The primer sequences used are detailed in Table 2. Gene expression levels were evaluated using a Biorad CFX96 real-time PCR instrument (California, USA) with 2X SYBR green master mix (Nepenthe, Turkey). The GAPDH gene

Score	Vascular features	Extravascular alveolar involvement	Bronchiole features	
0	Normal	None	None	
1	Slight hyperemia	Mild edema and inflammatory reaction	Mild infiltration of inflammatory cells	
2	Moderate hyperemia	Moderate inflammatory reaction and areas of moderate alveolar thickening (25-50% visualized lung)	Moderate infiltration of inflammatory cells; detachment of lining in some bronchioles	
3	Severe hyperemia	Moderate-severe inflammatory exudate and severe alveolar thickening (> 50% visualized lung)	Complete loss of bronchiole structure; detachment of lining; cellular debris and inflammatory cell exudate	

Genes	Primary sequence	Product size	Accession number
CADDII (IlouseVeening)	F: AGTGCCAGCCTCGTCTCATA	248 bp	NM_017008.4
GAPDH (HouseKeeping)	R: GATGGTGATGGGTTTCCCGT	248 bp	
Company	F: AGCCAGATGCTGTCCCATAC	140 h	XM_039110693.1
Caspase 9	R: CAGGAACCGCTCTCTTCTTGTC	148 bp	
Company 12	F: CTGCATCAGAATCCAGGGGA	212 ha	NM_130422.1
Caspase 12	R: TCGGCCTTCCTTCCTTCTCCATCA	212 bp	
СНОР	F: TGGAAGCCTGGTATGAGGATCTG	175 he	XX4 00/241445 4
CHUR	R: GAGGTGCTTGTGACCTCTCTGCTG	175 bp	XM_006241445.4

Table 2. Primary sequences, product size, and accession numbers of genes that used in this study

F: Forward, R: Reverse, GAPDH: glyceraldehyde-3-phosphate dehydrogenase, CHOP: C/EBP homologous protein

served as the housekeeping gene in the study. The reaction mixture, prepared according to the kit manufacturer's protocol, reached a final volume of 20 µl. This mixture was loaded into a real-time qPCR device following the kit's instructions, and each sample was analyzed in triplicate. PCR conditions consisted of an initial denaturation at 94 °C for 10 min, followed by 40 cycles of denaturation at 95 °C for 15 sec, and annealing/extension at 55 °C for 30 sec. Relative mRNA levels were determined by applying the 2- $\Delta\Delta Ct$ formula to the normalized results.

Statistical analysis

For statistical analysis, we used the GraphPad Prism 10 (Version 10.1.0) (GraphPad Software, USA) program. Initially, the data were analyzed for normality of distribution using the Shapiro-Wilk test. Since the data showed a normal distribution (P>0.05), comparisons between the groups were made with one-way analysis of variance (ANOVA). The Tukey test was used to identify differences between groups, with values of P<0.05 considered statistically significant. For nonparametric data, the Mann-Whitney U test and Dunnett's C test were used to detect differences between groups.

Results

Biochemical results

In the LPS group, there was a significant increase in TOS

values and a decrease in TAS values compared to the control group (P=0.023 and P=0.031, respectively). The OSI values in this group showed a significant increase compared to the control group (P=0.003). In the LPS+FLV group, although TOS and OSI values increased and TAS values decreased compared to the control group, these changes were not statistically significant (P>0.05). Conversely, in the FLV group, there was a significant decrease in TOS and OSI values compared to the LPS group (P=0.001 and P<0.001, respectively). Additionally, there was a notable increase in TAS values in the FLV group compared to the LPS group (P<0.008), as illustrated in Figure 2.

Histopathological results

The lung histopathology of both the Control and FLV groups revealed normal tissue appearance. In the LPS group, marked hyperemia, increased septal tissue thickness, hemorrhage, and inflammatory cell infiltrations were observed compared to the control group. The pathological findings in the LPS+FLV group were mitigated through FLV treatment, as depicted in Figure 3.

Immunohistochemical findings

Slides from the control group's immunohistochemical staining revealed either no or very little Cas-3 and TNF- α expression. Cas-3 and TNF- α expressions significantly




Figure 2. Statistical analysis of oxidative stress parameters of this study Values are presented as means±standard deviation. A one-way ANOVA test was used. * $P \le 0.05$, ** $P \le 0.01$, *** $P \le 0.001$ LPS: Lipopolysaccharide, FLV: Fluvoxamine, TAS: Total anti-oxidant status, TOS: Total oxidant status, OSI: Oxidative stress index






Figure 3. Histopathological appearance of lungs among the groups of rats (A) Normal lung histology in the control group. (B) Hyperemia (arrowhead) and increased septal tissue thickness (arrow) in lungs in the LPS group. (C) Decreased septal tissue thickness (arrow) and pathological findings in the LPS+FLV group. (D) Normal tissue architecture of the FLV group, HE, scale bars=50 μ m. Values are presented as means±standard deviation. A one-way ANOVA test was used. * *P*≤0.05, ** *P*≤0.001, *** *P*≤0.001

increased in the LPS group (P=0.001 for both). After FLV therapy, Cas-3 and TNF- α expression also significantly decreased (P=0.001 for both). The FLV group's expressions matched those of the control group with markers in terms of similarity. Inflammatory cells, alveolar macrophages, and alveolar epithelial cells often exhibited expressions. The results of a statistical analysis of immunohistochemistry expressions are shown in Figure 4.

Genetic results

In the LPS group, the expression levels of Cas-9, Cas-12, and CHOP exhibited a significant increase compared to the control group (P=0.001 for all). However, in the LPS+FLV group, treatment with FLV led to a significant reversal of these parameters compared to the LPS group (P=0.001 for all). Notably, in the FLV group alone, the levels of Cas-9, Cas-12, and CHOP showed a significant decrease compared




Figure 4. Immuno expressions of Cas-3 (upper row) and TNF- α (below row) in lung tissues of rats (A) Negative expression in the control group. (B) Marked increase in (arrows) in LPS group. (C) Decreased expression in the LPS+FLV group. (D) No immuno expression in the FLV group. Streptavidin biotin peroxidase method, scale bars=50 μ m. Values are presented as means±standard deviation. A one-way ANOVA test was used. * $P \leq 0.05$, ** $P \leq 0.01$ LPS: Lipopolysaccharide, FLV: Fluvoxamine, Cas-3: Caspase-3, TNF-a: Tumor necrosis factor-alpha




Figure 5. Expression levels of Cas-9, Cas-12, and CHOP in lung tissues of rats Values are presented as means±standard deviation. A one-way ANOVA test was used. * $P \le 0.05$, ** $P \le 0.01$, *** $P \le 0.001$ LPS:Lipopolysaccharide, LPS+FLV: Lipopolysaccharide+Fluvoxamine, FLV: Fluvoxamine, Cas-9: Caspase-9, Cas-12: Caspase-12, CHOP: C/EBP homologous protein

to the LPS group (P=0.001 for all)(Figure 5). The probable mechanism of FLV's healing effect on LPS-induced lung injury is shown in Figure 6.

Discussion

In this study, we aimed to investigate the potential protective effects of FLV against sepsis-associated ALI through modulation of apoptotic and inflammatory pathways and ER stress. Sepsis is a life-threatening condition characterized by a dysregulated host response to infection, often leading to multiple organ dysfunction, with the lungs being particularly susceptible. ALI, a common complication of sepsis, involves inflammation, oxidative stress, and apoptosis, contributing to tissue damage and respiratory dysfunction. FLV, an antidepressant known for its anti-




Figure 6. Probable mechanism of Fluvoxamine's healing effect on lipopolysaccharide (LPS)-induced lung injury of rats

inflammatory and anti-oxidant properties, has recently garnered attention for its potential therapeutic effects beyond psychiatric disorders. However, its role in mitigating sepsis-induced lung injury remains underexplored. By investigating the apoptotic pathways modulated by FLV in the context of sepsis-related ALI, we aim to contribute to a deeper understanding of its potential as a therapeutic agent in critical care settings.

In diseases like sepsis, which can affect multiple organs, brain tissue damage may occur due to increased blood-brain barrier permeability caused by the heightened systemic inflammatory response aimed at combating the bacterial agent, while highly vascularized tissues such as the heart and lungs can also suffer significant damage (22). When both the brain and peripheral organs are affected, patients often exhibit severe clinical symptoms that complicate treatment, and inadequate protocols may result in peripheral organ damage along with psychiatric conditions like depression, especially in intensive care patients (23-26). This damage is linked to oxidative stress and inflammation caused not only by the bacterial agent but also by pro-oxidant and pro inflammatory substances circulating in the bloodstream, which target specific receptors in these tissues (22, 27). More serious mechanisms, such as apoptosis, leading to cell death, may also be triggered, contributing to conditions like depression (28-32). Antidepressants like FLV, which possess anti-inflammatory and anti-oxidant properties in addition to their primary therapeutic effects, offer additional benefits in treatment (33-35). This study explores the protective effects of FLV on lung tissue, focusing on its potential to mitigate organ damage beyond the central nervous system.

It is known that oxidative stress is also provoked in lung tissue in LPS-induced damage, which serves as a model for systemic inflammatory response (36-40). According to the biochemical analyses in this study, the increased TOS and decreased TAS values in the LPS group indicate the development of oxidative stress in lung tissue. The observation that these values were partially reversed with FLV treatment, albeit not significantly, may be attributed to insufficient drug administration. This warrants further investigation in other studies by exploring higher doses or repeated drug administration. Additionally, the fact that the FLV alone group did not decrease the levels of oxidant substances or significantly increase the levels of antioxidant enzymes compared to the control group suggests the involvement of other mechanisms.

Oxidative stress is known to trigger inflammation through the activation of certain intracellular pathways. Considering the histopathological and immunohistochemical findings in this study, it can be inferred that such activation occurred. The marked hyperemia, increased septal tissue thickness, inflammatory cell infiltrations, and heightened TNF-a expressions observed in the lung tissues of the LPS group indicate the development of inflammation. The significant reversal of these parameters with FLV treatment demonstrates the potential protective effect of the drug on lung tissue. Moreover, it appears that the anti-inflammatory activity takes precedence over the anti-oxidant activity in this protection. The ability of FLV to suppress the increased TNF- α levels in lung tissues induced by acute inflammation, even with a single dose, suggests its potential utility in similar acute events. There exists a close association between inflammation and apoptosis, a more serious condition. TNF-a released from inflammatory cells at the site of damage is known to activate its own receptor-mediated intracellular pathways, leading to apoptosis by upregulating the expression of Cas-3, the final step in these pathways (41-50). The increased TNF-a expressions detected in immunohistochemical analysis, along with the parallel increase in Cas-3 expression in alveolar macrophages, inflammatory cells, and alveolar epithelium, highlight this scenario. Changes in Cas-3 expression may be mediated by ERS and mitochondria or directly by TNF-a.

The intracellular signaling mechanism activated by TNF- α stimulation can trigger caspase-8-mediated Cas-3 activation, as well as stimulate mitochondria-mediated Cas-9 and Cas-3 expressions by increasing JNK expressions. Furthermore, while Cas-12-mediated Cas-3 expression may be directly increased as a result of ERS, mitochondria may be influenced by CHOP signaling, and Cas-9-mediated Cas-3 expression may be triggered, ultimately resulting in apoptosis (51-60). In this study, the increase in Cas-12 expressions detected in the lung tissues of the LPS group indicates the involvement of ERS. In contrast, the increase in CHOP and Cas-9 expressions indicates mitochondrial stress. The fact that FLV leads to a decrease in both TNF- α and these expressions suggests that the drug can mitigate apoptosis secondary to inflammation or directly.

Furthermore, the scarcity of literature demonstrating the antiapoptotic properties of FLV, especially its effects on lung tissue, underscores the innovative aspect of this study. Limitations of this study include the use of a single drug dose, lack of testing for different doses, and absence of protein-level support for genetic analyses with western blot analyses.

Conclusion

This study has demonstrated that FLV, an effective antidepressant, suppresses the inflammatory and apoptotic processes induced by systemic inflammation in lung tissue. Future studies should focus on conducting more detailed analyses of this activity, including exploring different intracellular pathways. It would be advisable to complement such molecular research with clinical studies for a comprehensive understanding of FLV's therapeutic effects in the context of lung inflammation.

Acknowledgment

Thanks to Suleyman Demirel University Scientific Research Project Unit (SDU-BAP) (project number TSG-2023-9010) for supporting this study.

Authors' Contributions

H A, O O, S T, and R T designed this study and revised the article. SE A, HE C, and A B performed the experiment. O K, A B, and A G analyzed the data. H A and O O drafted this article. All authors approved the finalized manuscript.

Conflicts of Interest

The authors declare that they have no conflicts of interest.

Declaration

We have not used any AI tools or technologies to prepare this manuscript.

Ethical Approval

The procedures carried out on rats were reviewed and approved by the Animal Experiments Local Ethics Committee of Suleyman Demirel University (Ethics No: 26.01.2023-121/01).

References

1. Zhou Y, Li Q-X, Liao Z-Z, Liu Y, Ouyang Y, Jiang W-J, *et al.* Antiinflammatory effect and component analysis of Chaihu Qingwen granules. J Ethnopharmacol 2023; 317: 116763.

2. Grommes J, Soehnlein O. Contribution of neutrophils to acute lung injury. Mol Med 2011; 17: 293-307.

3. Li J, Lu K, Sun F, Tan S, Zhang X, Sheng W, *et al.* Panaxydol attenuates ferroptosis against LPS-induced acute lung injury in mice by Keap1-Nrf2/HO-1 pathway. J Transl Med 2021; 19: 96-110.

4. Shen X, Chen H, Zhang H, Luo L, Wen T, Liu L, *et al.* A natural sesquiterpene lactone isolinderalactone attenuates lipopolysaccharide-induced inflammatory response and acute lung injury through inhibition of NF- κ B pathway and activation Nrf2 pathway in macrophages. Int Immunopharmacol 2023; 124: 110965.

5. Brognara F, Castania JA, Dias DPM, Kanashiro A, Salgado HC. Time course of hemodynamic responses to different doses of lipopolysaccharide in unanesthetized male rats. Front Physiol 2019; 10: 771-779.

6. Ghosh AP, Klocke BJ, Ballestas ME, Roth KA. CHOP potentially Co-Operates with FOXO3a in neuronal cells to regulate PUMA and BIM expression in response to ER stress. PLoS One 2012; 7:e39586-39597.

7. Lai E, Teodoro T, Volchuk A. Endoplasmic reticulum stress: Signaling the unfolded protein response. Physiology 2007; 22: 193-201.

8. Wei MC, Zong W-X, Cheng EH-Y, Lindsten T, Panoutsakopoulou V, Ross AJ, *et al.* Proapoptotic BAX and BAK: A requisite gateway to mitochondrial dysfunction and death. Science (1979) 2001; 292: 727-730.

9. Ishiwata K, Hashimoto K. Sigma receptor ligands: Possible application as therapeutic drugs and as radiopharmaceuticals. Curr Pharm Des 2006; 12: 3857-3876.

10. Tanimukai H, Kudo T. Fluvoxamine alleviates paclitaxelinduced neurotoxicity. Biochem Biophys Rep 2015; 4: 202-206.

11. Barmoudeh Z, Sadeghi H, Gheitasi I, Khalvati B, Omidifar N, Azizi M, *et al.* Fluvoxamine ameliorates oxidative stress and inflammation induced by bile-duct ligation in male rats. Heliyon 2022; 8: e12344-12351.

12. Hosszu A, Toth AR, Lakat T, Stepanova G, Antal Z, Wagner LJ, *et al.* The sigma-1 receptor is a novel target for improving cold preservation in rodent kidney transplants. Int J Mol Sci 2023; 24:

11630-11640.

13. Cao C, Gao T, Cheng M, Xi F, Zhao C, Yu W. Mild hypothermia ameliorates muscle wasting in septic rats associated with hypothalamic AMPK-induced autophagy and neuropeptides. Biochem Biophys Res Commun 2017; 490: 882-888.

14. Rafiee L, Hajhashemi V, Javanmard SH. Fluvoxamine inhibits some inflammatory genes expression in LPS/stimulated human endothelial cells, U937 macrophages, and carrageenan-induced paw edema in rat. Iran J Basic Med Sci 2016; 19: 977-984.

15. Erel O. A novel automated direct measurement method for total antioxidant capacity using a new generation, more stable ABTS radical cation. Clin Biochem 2004; 37: 277–285.

16. Erel O. A new automated colorimetric method for measuring total oxidant status. Clin Biochem 2005; 38: 1103-1111.

17. Savas HB, Gultekin F, Ciris IM. Positive effects of meal frequency and calorie restriction on antioxidant systems in rats. North Clin Istanb 2017; 4: 109-116.

18. Luna GL. Manual of Histologic Staining Methods of the Armed Forces Institute of Pathology. 3rd ed. (pp. 32–34). New York: McGraw Hill Book, 1968.

19. Passmore MR, Byrne L, Obonyo NG, See Hoe LE, Boon AC, Diab SD, *et al.* Inflammation and lung injury in an ovine model of fluid resuscitated endotoxemic shock. Respir Res 2018; 19: 231-241.

20. Ozmen O, Milletsever A, Tasan S, Selcuk E, Savran M. The effects of cannabidiol against Methotrexate-induced lung damage. Basic Clin Pharmacol Toxicol 2024; 134: 695-703.

21. Karakuyu NF, Özseven A, Akın SE, Çamaş HE, Özmen Ö, Cengiz Ç. L-carnitine protects the lung from radiation-induced damage in rats via the AMPK/SIRT1/TGF-1ß pathway. Naunyn Schmiedebergs Arch Pharmacol 2024; 397: 8043-8051.

22. Hu Y, He S, Xu X, Cui X, Wei Y, Zhao C, *et al.* Shenhuangdan decoction alleviates sepsis-induced lung injury through inhibition of GSDMD-mediated pyroptosis. J Ethnopharmacol 2024; 318.

 Garcez-Leme LE, Avelino-Silva TJ. Depression, delirium, and post-intensive care syndrome. Int Psychogeriatr 2023; 35: 399-401.
 Pulak LM, Jensen L. Sleep in the intensive care unit: A review. J Intensive Care Med 2016; 31: 14-23.

25. Stuck A, Clark MJ, and Connelly CD. Preventing intensive care unit delirium: A patient-centered approach to reducing sleep disruption. Dimens Crit Care Nurs 2011; 30: 315-320.

26. Thomason JWW, Shintani A, Peterson JF, Pun BT, Jackson JC, Ely EW. Intensive care unit delirium is an independent predictor of longer hospital stay: A prospective analysis of 261 non-ventilated patients. Crit Care 2005; 9: 375-381.

27. Li Q, Xiang Y, Zhang Z, Qu X, Wu J, Fu J, *et al.* An integrated RNA-Seq and network pharmacology approach for exploring the preventive effect of Corydalis bungeana Turcz. Extract and Acetylcorynoline on LPS-induced acute lung injury. J Ethnopharmacol 2024; 318: 117048.

28. Elmore S. Apoptosis: A review of programmed cell death. Toxicol Pathol 2007; 35: 495-516.

29. Vitale I, Pietrocola F, Guilbaud E, Aaronson SA, Abrams JM, Adam D, *et al.* Apoptotic cell death in disease-Current understanding of the NCCD 2023. Cell Death Differ 2023; 30: 1097-1154.

30. Orrenius S, Nicotera P, Zhivotovsky B. Cell death mechanisms and their implications in toxicology. Toxicol Sci 2011; 119: 3-19.

31. Huang J, Zhu Y, Li S, Jiang H, Chen N, Xiao H, *et al.* Licochalcone B confers protective effects against LPS-Induced acute lung injury in cells and mice through the Keap1/Nrf2 pathway. Redox Rep 2023; 28: 2243423-2243433.

32. Shen J, Zhang P, Li Y, Fan C, Lan T, Wang W, *et al.* Neuroprotective effects of microRNA-211-5p on chronic stress-induced neuronal apoptosis and depression-like behaviours. J Cell Mol Med 2021; 25: 7028-7038.

33. Xie X, Wu X, Zhao D, Liu Y, Du Q, Li Y, *et al.* Fluvoxamine alleviates bleomycin-induced lung fibrosis via regulating the cGAS-STING pathway. Pharmacol Res 2023; 187: 106577-106590. 34. Naji Esfahani H, Rafiee L, and Haghjooy Javanmard S.

Evaluation of the effect of antidepressant drug, fluvoxamine, on cyclooxygenase-2 protein expression in lipopolysaccharidestimulated macrophages. Adv Biomed Res 2019; 8: 5-9.

35. Fenton C, Lee A. Antidepressants with anti-inflammatory properties may be useful in long COVID depression. Drugs Ther Perspect 2023; 39: 65-70.

36. Bezerra FS, Lanzetti M, Nesi RT, Nagato AC, Silva CPE, Kennedy-Feitosa E, *et al.* Oxidative stress and inflammation in acute and chronic lung injuries. Antioxidants (Basel) 2023: 21;12: 548-594.

37. Kratzer E, Tian Y, Sarich N, Wu T, Meliton A, Leff A, *et al.* Oxidative stress contributes to lung injury and barrier dysfunction via microtubule destabilization. Am J Respir Cell Mol Biol 2012;47: 688-697.

38. Valenca SS, Silva Bezerra F, Lopes AA, Romana-Souza B, Marinho Cavalcante MC, Lima AB, *et al.* Oxidative stress in mouse plasma and lungs induced by cigarette smoke and lipopolysaccharide. Environ Res 2008;108: 199-204.

39. Dong Z, Yuan Y. Accelerated inflammation and oxidative stress induced by LPS in acute lung injury: Inhibition by ST1926. Int J Mol Med 2018; 41: 3405-3421.

40. Mo M, Li S, Dong Z, Li C, Sun Y, Li A, *et al*. S-allylmercaptocysteine ameliorates lipopolysaccharide-induced acute lung injury in mice by inhibiting inflammation and oxidative stress via nuclear factor kappa B and Keap1/Nrf2 pathways. Int Immunopharmacol 2020;81:106273.

41. Li X, Shi J, Teng Y, Liu Z. The preventative effect of Baihe Gujin Pill on cisplatin-induced acute kidney injury by activating the PI3K/AKT and suppressing the NF-κB/MAPK pathways. J Ethnopharmacol 2024; 318: 117071.

42. Zhao H, Wu L, Yan G, Chen Y, Zhou M, Wu Y, *et al.* Inflammation and tumor progression: signaling pathways and targeted intervention. Signal Transduct Target Ther 2021; 6: 263-309.

43. van Loo G, Bertrand MJM. Death by TNF: A road to inflammation. Nat Rev Immunol 2023; 23: 289-303.

44. Webster JD, Vucic D. The balance of TNF mediated pathways regulates inflammatory cell death signaling in healthy and diseased tissues. Front Cell Dev Biol 2020; 8: 365-379.

45. Choi Y, Cho YL, Park S, Park M, Hong KS, Park YJ, *et al.* Anti-inflammatory effects of Idebenone attenuate LPS-induced systemic inflammatory diseases by suppressing NF-κB activation. Antioxidants (Basel) 2024;13: 151-165.

46. Lee HJ, Park JH, Hoe HS. Idebenone Regulates A β and LPSinduced neurogliosis and cognitive function through inhibition of NLRP3 inflammasome/IL-1 β axis activation. Front Immunol 2022; 13: 749336-749350.

47. Mannino F, Urzì Brancati V, Lauro R, Pirrotta I, Rottura M, Irrera N, *et al.* Levosimendan and Dobutamin attenuate LPSinduced inflammation in microglia by inhibiting the NF- κ B pathway and NLRP3 inflammasome activation via Nrf2/HO-1 signalling. Biomedicines 2024; 12: 1009-1025.

48. Pizzino G, Irrera N, Cucinotta M, Pallio G, Mannino F, Arcoraci V, *et al.* Oxidative stress: Harms and benefits for human health. Oxid Med Cell Longev 2017; 2017: 8416763-8416776.

49. Reuter S, Gupta SC, Chaturvedi MM, Aggarwal BB. Oxidative stress, inflammation, and cancer: How are they linked? Free Radic Biol Med 2010; 49: 1603-1616.

50. Olufunmilayo EO, Gerke-Duncan MB, Holsinger RMD. Oxidative stress and antioxidants in neurodegenerative disorders. Antioxidants (Basel) 2023; 12: 517-547.

51. Taabazuing CY, Okondo MC, Bachovchin DA. Pyroptosis and apoptosis pathways engage in bidirectional crosstalk in monocytes and macrophages. Cell Chem Biol 2017; 24: 507-514.

52. Ni H, Ou Z, Wang Y, Liu Y, Sun K, Zhang J, *et al.* XBP1 modulates endoplasmic reticulum and mitochondria crosstalk via regulating NLRP3 in renal ischemia/reperfusion injury. Cell Death Discov 2023; 9: 69-81.

53. Yuan L, Cai Y, Zhang L, Liu S, Li P, Li X. Promoting apoptosis, a promising way to treat breast cancer with natural products: A

comprehensive review. Front Pharmacol 2022; 12: 801662-801707. 54. Li M, Kong Y, Guo W, Wu X, Zhang J, Lai Y, *et al.* Dietary aflatoxin B_1 caused the growth inhibition, and activated oxidative stress and endoplasmic reticulum stress pathway, inducing apoptosis and inflammation in the liver of northern snakehead (Channa argus). Sci Total Environ 2022; 850: 157997.

55. Parrish AB, Freel CD, Kornbluth S. Cellular mechanisms controlling caspase activation and function. Cold Spring Harb Perspect Biol 2013; 5: a008672-8896.

56. Zhang J, Wang X, Vikash V, Ye Q, Wu D, Liu Y, Dong W. ROS and ROS-mediated cellular signaling. Oxid Med Cell Longev 2016; 2016: 4350965-4350983.

57. Gough P, Myles IA. Tumor necrosis factor receptors: Pleiotropic signaling complexes and their differential effects. Front Immunol

2020; 11: 585880-585894.

58. Shu HB, Takeuchi M, Goeddel DV. The tumor necrosis factor receptor 2 signal transducers TRAF2 and c-IAP1 are components of the tumor necrosis factor receptor 1 signaling complex. Proc Natl Acad Sci U S A 1996; 93: 13973-13978.

59. Siegmund D, Wagner J, Wajant H. TNF receptor associated factor 2 (TRAF2) signaling in cancer. Cancers (Basel) 2022; 14: 4055-4083.

60. Chandra D, Choy G, Deng X, Bhatia B, Daniel P, Tang DG. Association of active caspase 8 with the mitochondrial membrane during apoptosis: Potential roles in cleaving BAP31 and caspase 3 and mediating mitochondrion-endoplasmic reticulum cross talk in etoposide-induced cell death. Mol Cell Biol 2004; 24: 6592-6607.